U.S. market Closed. Opens in 17 hours 3 minutes

ANIP | ANI Pharmaceuticals, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 55.93 - 59.04
52 Week Range 48.20 - 70.81
Beta 0.70
Implied Volatility 47.77%
IV Rank 69.67%
Day's Volume 280,044
Average Volume 321,814
Shares Outstanding 21,030,100
Market Cap 1,181,891,620
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
IPO Date 2000-05-05
Valuation
Profitability
Growth
Health
P/E Ratio 47.23
Forward P/E Ratio N/A
EPS 1.19
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 642
Country USA
Website ANIP
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
*Chart delayed
Analyzing fundamentals for ANIP we got that it has weak fundamentals where Valuation is considered to be slightly overvalued, Profitability is unacceptably poor, Growth is very bad and Health is passable. For more detailed analysis please see ANIP Fundamentals page.

Watching at ANIP technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on ANIP Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙